Venture Leaders Biotech 2024: 10 startups selected for Boston Roadshow
The Swiss Startup National Team welcomes new members: 10 startups have been selected for Venture Leaders Biotech 2024. The entrepreneurs will meet international investors and industry leaders during their roadshow and gain access to industry-specific expertise to develop their companies.
The ten start-ups selected by a jury of investors and biotech experts from over 70 applications will take part in the roadshow in Boston, one of the most important life science centers in the world. From May 13-17, 2024, the roadshow will bring the participants together with international investors and industry leaders to accelerate the expansion of their companies in the US.
The Venture Leaders Biotech will present themselves and their startups at a kick-off event at the Swiss Biotech Day in Basel on April 22, 2024.
The startups follow in the footsteps of high-profile former team members such as Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), SimplicityBio (acquired by Precision for Medicine), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105m funding round in 2023) and Interax Biotech (seed round with US investors met during the roadshow). With the biotech industry accounting for 39% of Swiss exports, the Venture Leaders Biotech program contributes to the continued strength and vitality of the sector.
"The preparation of this roadshow, which is already in its 18th edition, is a tribute to the quality of the innovations and startups that have been part of this journey" said Jordi Montserrat, co-founder and CEO of Venturelab. "I can't wait to be part of this new edition and support this new team in its international expansion."
"Thanks to our preparation, we were able to connect with VCs and pharma contacts during the roadshow, which opened up invaluable opportunities for us. The mix of youth and experience in our team has taught us to succeed together," said Mamta Chabria, co-founder and CEO of Tandem Therapeutics and Venture Leaders Biotech 2023 participant.
Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and supported by Debiopharm, EPFL, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, Novartis, Swiss Biotech Association and Vischer.
The Venture Leaders Biotech 2024:
Adoram Therapeutics is a Geneva-based multi-asset startup developing next-generation small molecule therapies for the treatment of cancer, inflammation and other diseases that are safer and more effective than conventional therapies thanks to an allosteric mode of action.
Allegria Therapeutics - St. Gallen
Allegria Therapeutics is a Basel-based biopharma startup founded in 2023 with the goal of building a differentiated portfolio of therapeutic approaches around biological targets that selectively modulate mast cells as triggers of allergies and inflammatory diseases. The startup focuses its efforts on sustainable innovation to combat the growing burden on patients and restore their quality of life.
Eviive's mission is to revolutionize precision medicine research and development and its application by intercepting once undetectable cell-to-cell communication to deliver novel, actionable biomarkers with the goal of achieving unmatched success in treating and curing patients.
inSEIT is dedicated to the bioinformatic design and improvement of immobilized enzymes to develop next-generation biocatalysts for the chemical industry. The focus is on sustainability, market introduction and cost efficiency, thus contributing to a greener future.
Kylys Aesthetics develops a biocompatible hyaluronic acid-based dermal filler designed for excellent injectability, long-lasting effect and stable placement at the injection site. The patented technology enables injections with an ultra-thin 34G needle, ensuring greater precision, less pain for the patient and less post-injection hematoma.
OBaris enables the painless administration of injectable drugs via the OctoPatch® - a small, needle-free buccal patch inspired by an octopus sucker. The proprietary platform enables easy and painless administration of various injectable drugs with minimal waste production.
Shape Biopharmaceuticals - Zurich
Shape Biopharmaceuticals combines deep immunobiology and medicinal chemistry expertise with innovative, computational protein design to develop cost-effective, next-generation immunotherapies that will change patients' lives.
TissueLabs specializes in advanced biofabrication and offers a comprehensive range of devices, biomaterials and services for the development of lab-grown organs and tissues. TissueLabs is dedicated to streamlining biofabrication and enabling groundbreaking research and therapeutic advances in the field.
Well Science is on a mission to revolutionize the treatment of respiratory allergies. We combine the best of nature with innovative science that we have gathered over 17 years. www.BlossomUp.com is the first natural product whose ingredients have been proven to contribute to a well-functioning, balanced immune system.
Ymmunobio was founded in 2021 and focuses on gastrointestinal (GI) cancers. The start-up's first-in-class platform produces an antibody-drug conjugate (ADC) candidate (YB-800ADC) that has tremendous potential for the treatment of gastrointestinal cancers. The novel receptor target is present in Ø50% of colorectal cancers.
Source and other information: www.venturelab.swiss / www.venture-leaders.ch
